Lirilumab, CAS 1000676-41-4

Product Description: Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478./[2]Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86.

CAS Number: 1000676-41-4

Molecular Weight: N/A

Compound Purity: 96.80

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Transmembrane Glycoprotein

• Artikelnummer: MEXHY-P99208-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99208-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated